Skip to main content
. 2024 Jul 4;29(7):10.1111/adb.13421. doi: 10.1111/adb.13421

FIGURE 3.

FIGURE 3

Interacting effects between the CB1 antagonist and mitigating (anxiolytic‐like) drug (i.e., HDAC inhibitor, CB1 agonist, or TRPV1 antagonist) against anxiety‐like behavioural alterations caused by NC and/or IM. The parameter values of the EPM test at the 2‐h time point after the last NC (0.8 mg/kg, sc) or IM (10 min) treatment are shown as means with SD bars (n = 10) for each mitigating drug plus CB1 antagonist group (with each ip dose [mg/kg]), and statistical significance in post hoc tests is denoted using the symbols as defined below. The detailed data and statistical results have been included in Table S3. (A) SB (100 mg/kg, ip) plus SR (1 mg/kg, ip) groups (SB + SR groups); (B) VA (300 mg/kg, ip) plus SR (1 mg/kg, ip) groups (VA + SR groups); (C) AC (0.2 mg/kg, ip) plus SR (1 mg/kg, ip) groups (AC + SR groups); (D) CZ (1 mg/kg, ip) plus SR (1 mg/kg, ip) groups (CZ + SR groups). **P < 0.01: significant attenuation as compared with the control group; ++P < 0.01: significant increase as compared with the NC, IM, or NC‐IM group without any cotreatments; $$P < 0.01: significant attenuation as compared with the IM group without any cotreatments; ##P < 0.01: significant attenuation as compared with the NC, IM, or NC‐IM group cotreated with the efficacious HDAC inhibitor, CB1 agonist, or TRPV1 antagonist.